Recent Finacing
Recent Raise
Arialys Therapeutics develops CNS-targeted precision antibody therapies that selectively neutralize pathogenic anti‑NMDAR autoantibodies, advancing lead candidate ART5803 from nonhuman-primate proof-of-concept toward IND‑enabling clinical studies for ANRE and autoimmune psychosis.
